PTH-080 Serious Infusion Reactions with Vedolizumab are Rare: A UK Multicenter Experience

作者
Peter Miles Irving,Charlie W. Lees,Ailsa L Hart,Karen Kemp,Tariq Ahmad,Fraser J.R. Cummings
出处
期刊:Gut [BMJ]
卷期号:: A258.2-A259 被引量:1
标识
DOI:10.1136/gutjnl-2016-312388.485
摘要

Introduction Vedolizumab has recently become widely available in the UK for the treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD). This has created pressure on infusion services exacerbated by the improved access to infliximab for UC and the ever increasing number of patients with CD receiving IFX. The UK Summary of Product Characteristics, unlike in the US, mandates post-infusion monitoring of patients for 2 hours after the first 2 infusions and for 1 hour after subsequent infusions. We have, therefore, reviewed the frequency of infusion reactions during and after infusions of vedolizumab in 6 UK IBD centres. Methods Details of the numbers of vials of vedolizumab supplied to each centre were provided by Takeda UK. All centres identified patients on vedolizumab who had had possible infusion-related reactions and reported the details after review of the case record. Results Across the 6 centres, 1132 vials of vedolizumab had been supplied for infusion up until 5th March 2016. 9 possible infusion reactions were identified involving 9 patients. 1 reaction occurred during the infusion, 1 in the 2 hours after the infusion and 7 more than 2 hours after the infusion. One anaphylactoid reaction occurred on the second infusion in a patient with Crohn’s disease on concomitant mercaptopurine. The infusion was stopped and no further infusions of vedolizumab were given. Other possible infusion-related reactions included headache (2), rash (3), nausea and blurred vision (1), vasovagal symptoms (1), and palpitations (1). Only one reaction occurred in the 2 hours following the infusion. This was a patient who experienced palpitations who had consumed several cups of coffee whilst waiting to be discharged. Other than the patient with an anaphylactoid reaction, none of the other reactions led to discontinuation of vedolizumab. Conclusion Vedolizumab infusion reactions are rare. Only one anaphylactoid reaction was seen in over 1000 infusions. No definite reactions occurred in the 2 hours after infusions suggesting that monitoring patients for 2 hours after the first 2 infusions and for 1 hour after subsequent infusions is probably unnecessary. Overall, the frequency of infusion reactions is low as was seen in the Gemini studies. Disclosure of Interest P. Irving Grant/research support from: AbbVie, MSD, Consultant for: AbbVie, MSD, Vifor, Genentech Inc., Takeda, Warner Chilcott, Falk and Pharmacosmos, Speaker bureau with: AbbVie, MSD, Ferring, Warner Chilcott, Shire, Falk and Johnson and Johnson, C. Lees: None Declared, A. Hart: None Declared, K. Kemp: None Declared, T. Ahmad: None Declared, F. Cummings: None Declared

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刘较瘦完成签到,获得积分10
刚刚
好运爆彭完成签到,获得积分10
1秒前
樊小雾完成签到,获得积分10
1秒前
Qinzhiyuan1990完成签到 ,获得积分10
1秒前
爱科研的Z完成签到,获得积分10
2秒前
princesun083完成签到,获得积分10
2秒前
ZeKaWa的应助被发呆采纳,获得10
2秒前
玩命的灵安完成签到,获得积分10
2秒前
科研通AI65的应助被月九采纳,获得10
3秒前
3秒前
汉堡包的应助被完美的映秋采纳,获得30
3秒前
4秒前
zhugeliu完成签到,获得积分10
4秒前
skmksd完成签到,获得积分10
4秒前
QIEZI完成签到 ,获得积分10
4秒前
万能图书馆的应助被zzx采纳,获得10
4秒前
小虫发布了新的文献求助10
4秒前
科研通AI6.4的应助被长风入林采纳,获得10
5秒前
5秒前
点点完成签到 ,获得积分10
6秒前
satellite完成签到,获得积分10
6秒前
6秒前
7秒前
YuLu完成签到 ,获得积分10
8秒前
张颖涛完成签到,获得积分10
8秒前
8秒前
高贵的大蒜完成签到 ,获得积分10
9秒前
suifeng91完成签到,获得积分10
9秒前
一棵树发布了新的文献求助10
9秒前
宁静完成签到 ,获得积分10
9秒前
yujuan完成签到,获得积分10
10秒前
拉扣完成签到,获得积分10
10秒前
长脚蟹完成签到,获得积分10
11秒前
金勇完成签到,获得积分10
11秒前
英姑的应助被elang采纳,获得10
12秒前
12秒前
dougsong发布了新的文献求助10
12秒前
12秒前
小柒完成签到 ,获得积分10
12秒前
Zzz完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039